



State of New Jersey
Department of Human Services
Division of Medical Assistance & Health Services

NEWSLETTER

Volume 32 No. 01

January 2022

TO: Providers of Pharmaceutical Services – **For Action**
Health Maintenance Organizations – **For Information Only**

SUBJECT: **Medicaid/NJ FamilyCare Fee-For-Service (FFS) Coverage of at-home SARS-CoV-2 test kits**

EFFECTIVE: Immediately

PURPOSE: To notify providers of pharmaceutical services of a policy change by the New Jersey Division of Medical Assistance and Health Services to provide Medicaid/NJ FamilyCare FFS coverage for at-home SARS-CoV-2 test kits.

BACKGROUND: The Centers for Medicare & Medicaid Services (CMS) has issued guidance on Medicaid and Children’s Health Insurance Program (CHIP) coverage and reimbursement for SARS-CoV-2 testing under the American Rescue Plan Act of 2021 (ARP). ARP SARS-CoV-2 testing coverage requirements include “point of care” or “home” tests that have been provided to a Medicaid or CHIP beneficiary by a qualified Medicaid or CHIP provider of SARS-CoV-2 testing tests. At-home testing includes those where a specimen is collected at home and then sent to a clinical laboratory or other certified testing site for testing, and those that are entirely performed at home, meaning the test system includes the ability to perform the test without involvement of a clinical laboratory.

To broaden access to SARS-CoV-2 testing under the American Rescue Plan Act of 2021, the Division is expanding Medicaid/NJ FamilyCare FFS coverage of SARS-CoV-2 testing to include at-home SARS-CoV-2 testing kits. The kits are available Over-the-Counter (OTC) and do not need to be prescribed by a healthcare professional.

ACTION: Pharmacists requesting payment for a SARS-CoV-2 test kit from the Medicaid/NJ FamilyCare Program must send a standard NCPDP D.0 claim transaction through the State’s point-of-sale (PO) claims processing system. When billing for at-home SARS-CoV-2 test kits, **pharmacists must report their pharmacy National Provider Identifier (NPI) in Field No. 411-DB within the NCPDP Claim Segment.** Pharmacists must assign an original prescription number with zero refills and the National Product Code (NDC) for each SARS-CoV-2 test kit dispensed. It is important to note that requesting claim payments requires reporting of a SARS-CoV-2 test kit’s NDC and not its Universal Product Code (UPC).

Listed below are at-home SARS-CoV-2 test kits covered by NJ FamilyCare/Medicaid. Additional kits may be covered in the future and providers should check the NJMMIS website for updates.

Reimbursement for at-home SARS-CoV-2 test kits is limited to no more than two (2) at-home SARS-CoV-2 test kits per date of service and no more than four (4) at-home SARS-CoV-2 test kits per month, for a total of eight (8) tests per month. Please note that a single test kit contains two tests.

Reimbursement for each test kit will be the lower of the usual and customary (U&C) price or \$25. In accordance with 42 C.F.R. § 447.512(b), pharmacies must provide a U&C price when submitting pharmacy claims for prescription and OTC (nonprescription) items. NJAC 10:51-1.10 defines U&C as the lowest price charged to the majority of the general public.

OTC Brand Name	NDC	Quantity of tests per kit	Reimbursement
BinaxNOW COVID-19 Antigen Self-Test	11877001140	2	Up to \$25
CareStart COVID-19 Antigen Home Test	50010022431	2	Up to \$25
InteliSwab COVID-19 Rapid Test	08337000158	2	Up to \$25
QuickVue At-Home COVID-19 Test	14613033972	2	Up to \$25

If you have any questions concerning this Newsletter, please contact Gainwell Technologies Provider Services at 1-800-776-6334.

RETAIN THIS NEWSLETTER FOR FUTURE REFERENCE